Trends in the Incidence of Fatal Prostate Cancer in the United States by Race

European Urology

Volumn 71, Issue 2, 2017, Pages 195-201

  Kelly, Scott P ^a,b   Rosenberg, Philip S ^a   Anderson, William F ^a   Andreotti, Gabriella ^a   Younes, Naji ^b   Cleary, Sean D ^b   Cook, Michael B ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Cancer trends; Cause specific mortality; Disease progression; Prostate cancer; Prostate specific antigen

Indexed keywords

ADULT; AGED; ARTICLE; BLACK PERSON; CANCER INCIDENCE; CANCER REGISTRY; CANCER SURVIVAL; CAUCASIAN; CAUSE OF DEATH; FATALITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RACE DIFFERENCE; UNITED STATES; AFRICAN AMERICAN; AGE; ETHNOLOGY; HEALTH DISPARITY; INCIDENCE; MIDDLE AGED; MORTALITY; PROSTATE TUMOR; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TRENDS;

AFRICAN AMERICANS; AGE FACTORS; AGED; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH STATUS DISPARITIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84997079377     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.05.011     Document Type: Article

References (30)

1. [1] Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66 (2016), 7–30.
2. [2] Ryerson, A.B., Eheman, C.R., Altekruse, S.F., et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer 122 (2016), 1312–1337.
3. [3] DeSantis, C., Naishadham, D., Jemal, A., Cancer statistics for African Americans, 2013. CA Cancer J Clin 63 (2013), 151–166.
4. [4] Merrill, R.M., Feuer, E.J., Warren, J.L., Schussler, N., Stephenson, R.A., Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol 150 (1999), 848–860.
5. [5] Stamey, T.A., Yang, N., Hay, A.R., McNeal, J.E., Freiha, F.S., Redwine, E., Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 (1987), 909–916.
6. [6] Welch, H.G., Albertsen, P.C., Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986–2005. J Natl Cancer Inst 101 (2009), 1325–1329.
7. [7] Wachtel, M.S., Nelius, T., Haynes, A.L., Dahlbeck, S., de Riese, W., PSA screening and deaths from prostate cancer after diagnosisA population based analysis. Prostate 73 (2013), 1365–1369.
8. [8] Etzioni, R., Tsodikov, A., Mariotto, A., et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 19 (2008), 175–181.
9. [9] Chu, K.C., Tarone, R.E., Freeman, H.P., Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97 (2003), 1507–1516.
10. [10] Vollmer, R.T., The dynamics of death in prostate cancer. Am J Clin Pathol 137 (2012), 957–962.
11. [11] Epstein, M.M., Edgren, G., Rider, J.R., Mucci, L.A., Adami, H.O., Temporal trends in cause of death among Swedish and US men with prostate cancer. J Natl Cancer Inst 104 (2012), 1335–1342.
12. [12] Kim, H.J., Fay, M.P., Feuer, E.J., Midthune, D.N., Permutation tests for joinpoint regression with applications to cancer rates. Stat Med 19 (2000), 335–351.
13. [13] Holford, T.R., The estimation of age, period and cohort effects for vital rates. Biometrics 39 (1983), 311–324.
14. [14] Rosenberg, P.S., Anderson, W.F., Age-period-cohort models in cancer surveillance research: ready for prime time?. Cancer Epidemiol Biomarkers Prev 20 (2011), 1263–1268.
15. [15] Etzioni, R., Gulati, R., Tsodikov, A., et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer 118 (2012), 5955–5963.
16. [16] Draisma, G., Etzioni, R., Tsodikov, A., et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101 (2009), 374–383.
17. [17] Feuer, E.J., Merrill, R.M., Hankey, B.F., Cancer surveillance series: interpreting trends in prostate cancer - part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 91 (1999), 1025–1032.
18. [18] Welch, H.G., Gorski, D.H., Albertsen, P.C., Trends in metastatic breast and prostate cancer - lessons in cancer dynamics. N Engl J Med 373 (2015), 1685–1687.
19. [19] Cooperberg, M.R., Vickers, A.J., Broering, J.M., Carroll, P.R., Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer 116 (2010), 5226–5234.
20. [20] Zeng, C., Wen, W., Morgans, A.K., Pao, W., Shu, X., Zheng, W., Disparities by race, age, and sex in the improvement of survival for major cancers: results from the national cancer institute surveillance, epidemiology, and end results (seer) program in the United States, 1990 to 2010. JAMA Oncol 1 (2015), 88–96.
21. [21] Aizer, A.A., Wilhite, T.J., Chen, M.H., et al. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer 120 (2014), 1532–1539.
22. [22] Mariotto, A.B., Etzioni, R., Krapcho, M., Feuer, E.J., Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer 109 (2007), 1877–1886.
23. [23] Cook, M.B., Rosenberg, P.S., McCarty, F.A., et al. Racial disparities in prostate cancer incidence rates by census division in the United States, 1999–2008. Prostate 75 (2015), 758–763.
24. [24] Ziehr, D.R., Mahal, B.A., Aizer, A.A., et al. Income inequality and treatment of African American men with high-risk prostate cancer. Urol Oncol, 33, 2015 18.e7–13.
25. [25] Powell, I.J., Dyson, G., Land, S., et al. Genes associated with prostate cancer are differentially expressed in African American and European American men. Cancer Epidemiol Biomarkers Prev 22 (2013), 891–897.
26. [26] Wallace, T.A., Prueitt, R.L., Yi, M., et al. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res 68 (2008), 927–936.
27. [27] Han, Y., Rand, K.A., Hazelett, D.J., et al. Prostate cancer susceptibility in men of African ancestry at 8q24. J Natl Cancer Inst, 108, 2016, djv431.
28. [28] Salinas, C.A., Tsodikov, A., Ishak-Howard, M., Cooney, K.A., Prostate cancer in young men: an important clinical entity. Nat Rev Urol 11 (2014), 317–323.
29. [29] Powell, I.J., Bock, C.H., Ruterbusch, J.J., Sakr, W., Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 183 (2010), 1792–1796.
30. [30] Drazer, M.W., Huo, D.Z., Schonberg, M.A., Razmaria, A., Eggener, S.E., Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol 29 (2011), 1736–1743.